Reported Friday, NeuroSense Therapeutics Receives Dual Nasdaq Non-Compliance Notices For Minimum Bid Price And $35M Market Value Requirements, Given Until September 29, 2026
Benzinga Newsdesk 7 months ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Notifications have no immediate effect on the listing or trading of the Company's securities on NasdaqNasdaq has provided the Company until September 29, 2026 to regain compliance with both requirementsThe Company
- Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
- Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements
- The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value
